QuantLogix ← VRTX scorecard
📅 VRTX Earnings Preview
Vertex Pharmaceuticals Incorporated Common Stock
Next report (est.)
11/03/2026
Countdown
6 days
EPS growth YoY
+8.0%
Revenue growth YoY
+12.5%
Options-implied earnings move
±2.7%
The at-the-money straddle prices a move to roughly $528.08 or $499.98 from $514.03 by 10/30/2026.
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
08/04/2026 ±2.8% +1.7% over-priced
05/05/2026 ±1.8% -1.3% over-priced
02/13/2026 ±2.6% +5.7% under-priced
11/04/2025 ±2.0% -1.0% over-priced
08/05/2025 ±2.3% -20.6% under-priced
05/06/2025 ±2.4% -10.0% under-priced
02/13/2025 ±2.5% +2.1% over-priced
11/05/2024 ±1.9% +5.7% under-priced
Across these reports, options implied an average ±2.3% move vs an actual average of 6.0% — the stock stayed inside the implied band 50% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $4.31 $3.3B $1.1B
Q1 FY2026 $4.02 $3.0B $1.0B
Q4 FY2025 — $3.2B $1.2B
Q3 FY2025 $4.20 $3.1B $1.1B
Analyst posture
Buy / Strong Buy
32
Hold
6
Sell
1
Stable: +4 net change 30d
Live 5-factor engine read: Buy · 61/100 Full scorecard →
Get alerted before every VRTX report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on VRTX before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Vertex Pharmaceuticals Incorporated Common Stock (VRTX) reports in 6 days, with the next report estimated for 11/03/2026. Across the last 8 reports, options priced an average ±2.3% earnings move while the stock actually moved 6.0% on average — the market has been roughly fair on VRTX's earnings risk. Fundamentals into the print: EPS up 8.0% year-over-year, revenue up 12.5%. QuantLogix's live 5-factor engine currently reads VRTX as a buy at 61/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →